Notice: This company has been marked as potentially delisted and may not be actively trading. Merrimack Pharmaceuticals (MACK) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock Analysis Merrimack Pharmaceuticals Short Interest DataMerrimack Pharmaceuticals (MACK) has a short interest of 842,500 shares. This marks a 3.26% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.9, indicating that it would take 5.9 days of the average trading volume of 396,929 shares to cover all short positions.Current Short Interest842,500 sharesPrevious Short Interest815,900 sharesChange Vs. Previous Month+3.26%Dollar Volume Sold Short$12.42 millionShort Interest Ratio5.9 Days to CoverLast Record DateApril 30, 2024Outstanding Shares14,790,000 sharesPercentage of Shares Shorted5.70%Today's Trading Volume0 sharesAverage Trading Volume396,929 sharesToday's Volume Vs. Average0% Short Selling Merrimack Pharmaceuticals? Sign up to receive the latest short interest report for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMACK Short Interest Over TimeMACK Days to Cover Over TimeMACK Percentage of Float Shorted Over Time Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Merrimack Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024842,500 shares $12.42 million +3.3%N/A5.9 $14.74 4/15/2024815,900 shares $11.98 million +12.9%N/A6.4 $14.68 3/31/2024722,800 shares $10.68 million -1.0%N/A6.2 $14.77 3/15/2024729,900 shares $10.76 million -5.7%N/A7 $14.74 2/29/2024774,100 shares $11.38 million -5.9%N/A8.4 $14.70 2/15/2024822,900 shares $12.10 million +7.9%N/A9.7 $14.70 Get the Latest News and Ratings for MACK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024763,000 shares $10.22 million +1.5%N/A16.8 $13.40 1/15/2024752,100 shares $9.91 million -3.8%N/A18.8 $13.17 12/31/2023781,400 shares $10.48 million -10.4%N/A20.1 $13.41 12/15/2023871,600 shares $11.54 million -3.6%N/A23.4 $13.24 11/30/2023904,300 shares $11.41 million -1.8%N/A26.4 $12.62 11/15/2023921,100 shares $11.76 million -0.5%N/A27 $12.77 10/31/2023926,100 shares $11.33 million -2.6%N/A27.2 $12.23 10/15/2023951,100 shares $11.67 million -3.5%N/A21.3 $12.27 9/30/2023985,100 shares $12.15 million -5.3%N/A19.1 $12.33 9/15/20231,040,000 shares $12.73 million -2.8%N/A10.5 $12.24 8/31/20231,070,000 shares $13.06 million -2.7%N/A10.2 $12.21 8/15/20231,100,000 shares $13.38 million +1.9%N/A10.2 $12.16 7/31/20231,080,000 shares $12.97 million +3.9%N/A9.4 $12.01 7/15/20231,040,000 shares $12.15 million +5.4%N/A9.5 $11.68 6/30/2023986,900 shares $12.14 million +38.3%N/A9.2 $12.30 6/15/2023713,500 shares $8.84 million +4.4%N/A7.4 $12.39 5/31/2023683,700 shares $8.56 million -5.1%N/A9.2 $12.52 5/15/2023720,200 shares $9.20 million -8.8%N/A9.5 $12.77 4/30/2023789,600 shares $9.80 million -12.7%6.0%9.8 $12.41 4/15/2023904,700 shares $11.62 million +6.7%6.9%9.9 $12.84 3/31/2023847,700 shares $10.42 million -5.2%6.5%7 $12.29 3/15/2023894,500 shares $10.33 million -4.7%6.9%6.2 $11.55 2/28/2023938,100 shares $10.77 million -2.7%7.7%6 $11.48 2/15/2023964,000 shares $11.24 million +3.6%7.4%5.9 $11.66 1/31/2023930,300 shares $10.78 million +11.1%7.1%1.2 $11.59 1/15/2023837,100 shares $10.13 million +4.1%6.4%1.1 $12.10 12/30/2022804,300 shares $9.22 million +60.9%7.2%1.1 $11.46 12/15/2022499,800 shares $5.77 million -23.1%4.5%0.7 $11.55 11/30/2022649,800 shares $7.74 million -23.1%5.8%1 $11.91 11/15/2022844,700 shares $10.39 million +226.0%7.5%1.3 $12.30 10/31/2022259,100 shares $976,807.00 +1.0%2.3%0.5 $3.77 10/15/2022256,600 shares $857,044.00 -0.8%2.3%7 $3.34 9/30/2022258,700 shares $970,125.00 +2.0%2.3%8 $3.75 9/15/2022253,700 shares $1.11 million -2.8%2.3%8.7 $4.38We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol 8/31/2022261,000 shares $1.08 million +0.9%2.3%8.8 $4.15 8/15/2022258,800 shares $1.09 million -0.7%2.3%9.2 $4.22 7/31/2022260,600 shares $1.33 million -1.9%2.3%9.7 $5.09 7/15/2022265,500 shares $1.53 million -1.2%2.4%20.7 $5.75 6/30/2022268,700 shares $1.60 million -7.5%2.4%16.8 $5.95 6/15/2022290,500 shares $1.62 million +3.1%2.6%17.4 $5.57 5/31/2022281,700 shares $1.46 million +3.7%2.2%17.4 $5.18 5/15/2022271,700 shares $1.43 million -1.6%2.1%14.3 $5.25 4/30/2022276,100 shares $1.60 million +1.8%2.1%10.5 $5.80 4/15/2022271,300 shares $1.68 million -12.7%2.1%7.8 $6.21 3/31/2022310,800 shares $1.97 million -2.8%2.4%6.8 $6.33 3/15/2022319,800 shares $1.98 million -0.4%2.5%7.1 $6.20 2/28/2022321,100 shares $2.00 million -30.6%2.5%7.2 $6.24 2/15/2022462,600 shares $2.89 million -9.5%3.5%10.3 $6.24 1/31/2022511,300 shares $2.65 million +3.9%3.9%12.8 $5.18 1/15/2022491,900 shares $2.28 million +11.6%3.8%17 $4.64 12/31/2021440,600 shares $1.72 million +26.1%3.4%24.2 $3.91 12/15/2021349,300 shares $1.40 million -1.7%2.7%17.4 $4.01 11/30/2021355,200 shares $1.49 million -0.8%2.7%18.3 $4.20 11/15/2021357,900 shares $1.59 million +4.4%2.7%18.2 $4.43 10/29/2021342,900 shares $1.47 million -1.6%2.6%16.7 $4.30 10/15/2021348,600 shares $1.77 million +1.5%2.7%15.6 $5.08 9/30/2021343,600 shares $1.66 million -1.8%2.6%15.6 $4.83 9/15/2021350,000 shares $1.53 million +6.5%2.7%16.8 $4.38 8/31/2021328,600 shares $1.65 million -1.8%2.5%15.4 $5.02 8/13/2021334,600 shares $1.62 million -1.4%2.5%15.1 $4.84 7/30/2021339,500 shares $1.90 million +1.0%2.6%14 $5.60 7/15/2021336,100 shares $2.07 million -3.8%2.6%13.3 $6.15 6/30/2021349,200 shares $2.23 million +3.5%2.7%10.4 $6.39 6/15/2021337,500 shares $2.15 million +2.1%2.6%9.5 $6.36 5/28/2021330,700 shares $2.12 million +0.8%2.5%8.4 $6.40 5/14/2021328,000 shares $2.00 million -1.4%2.5%6.5 $6.10 4/30/2021332,800 shares $2.41 million -10.0%2.5%4.2 $7.25 4/15/2021369,900 shares $2.45 million +0.7%2.8%4.3 $6.62 3/31/2021367,200 shares $2.33 million -19.4%2.8%4 $6.34 3/15/2021455,400 shares $3.23 million -21.0%3.5%4.1 $7.10 2/26/2021576,500 shares $3.98 million -2.2%4.4%2.1 $6.91 2/12/2021589,400 shares $4.75 million +8.1%4.5%0.4 $8.06 1/29/2021545,500 shares $3.68 million -2.6%4.2%0.4 $6.75 1/15/2021560,100 shares $4.55 million -0.1%4.3%0.4 $8.13 12/31/2020560,900 shares $3.87 million -38.5%4.3%0.4 $6.90 12/15/2020911,400 shares $6.70 million +39.1%6.9%0.7 $7.35 11/30/2020655,100 shares $2.51 million +23.5%5.0%0.5 $3.83 11/15/2020530,300 shares $1.99 million +6.5%4.0%17.7 $3.76 10/30/2020497,900 shares $1.90 million +3.0%3.8%13.2 $3.81 10/15/2020483,300 shares $1.91 million -2.8%3.7%11.9 $3.95 9/30/2020497,300 shares $1.99 million -3.4%3.8%11.9 $4.00 9/15/2020514,900 shares $1.96 million -2.9%3.9%11.8 $3.80 8/31/2020530,100 shares $2.19 million +0.3%4.0%11.8 $4.13 8/14/2020528,700 shares $2.27 million -0.7%4.0%12.5 $4.30We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol 7/31/2020532,300 shares $1.77 million +0.4%4.1%20.3 $3.32 7/15/2020530,400 shares $1.71 million +8.4%4.1%20.5 $3.22 6/30/2020489,200 shares $1.63 million +1.1%3.8%13.8 $3.33 6/15/2020484,000 shares $1.52 million -1.7%3.7%12.2 $3.15 5/29/2020492,500 shares $1.64 million -4.4%3.8%12 $3.33 5/15/2020515,300 shares $1.86 million -3.5%4.0%12 $3.60 4/30/2020533,900 shares $1.97 million +3.7%4.1%12.1 $3.69 4/15/2020515,100 shares $1.79 million +8.8%4.0%11.3 $3.48 3/31/2020473,500 shares $1.70 million -1.4%3.7%11 $3.58 3/13/2020480,300 shares $1.68 million -2.6%3.8%17.9 $3.50 2/28/2020493,200 shares $858,168.00 +2.3%3.9%12.5 $1.74 2/14/2020482,200 shares $1.40 million -1.7%3.9%11.3 $2.90 1/31/2020490,500 shares $1.49 million -2.1%3.9%10.9 $3.03 1/15/2020501,100 shares $1.55 million -6.1%4.0%12 $3.10 12/31/2019533,500 shares $1.91 million -6.8%4.2%14 $3.58 MACK Short Interest - Frequently Asked Questions What is Merrimack Pharmaceuticals' current short interest? Short interest is the volume of Merrimack Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 842,500 shares of MACK short. Learn More on Merrimack Pharmaceuticals' current short interest. What is a good short interest ratio for Merrimack Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MACK shares currently have a short interest ratio of 6.0. Learn More on Merrimack Pharmaceuticals's short interest ratio. Is Merrimack Pharmaceuticals' short interest increasing or decreasing? Merrimack Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 842,500 shares, an increase of 3.3% from the previous total of 815,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Merrimack Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biotechnology" compare to Merrimack Pharmaceuticals: Ironwood Pharmaceuticals, Inc. (7.20%), Sangamo Therapeutics, Inc. (7.17%), Emergent BioSolutions Inc. (13.32%), Codexis, Inc. (2.11%), Rigel Pharmaceuticals, Inc. (2.73%), XOMA Co. (0.96%), Vanda Pharmaceuticals Inc. (5.60%), Verastem, Inc. (5.11%), Lexicon Pharmaceuticals, Inc. (12.80%), Achieve Life Sciences, Inc. (8.32%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Merrimack Pharmaceuticals stock? Short selling MACK is an investing strategy that aims to generate trading profit from Merrimack Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Merrimack Pharmaceuticals? A short squeeze for Merrimack Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MACK, which in turn drives the price of the stock up even further. How often is Merrimack Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MACK, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies Ironwood Pharmaceuticals Short Interest Sangamo Therapeutics Short Interest Emergent BioSolutions Short Interest Codexis Short Interest Rigel Pharmaceuticals Short Interest XOMA Short Interest Vanda Pharmaceuticals Short Interest Verastem Short Interest Lexicon Pharmaceuticals Short Interest Achieve Life Sciences Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MACK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merrimack Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MACK Stock Alerts